Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluorometholone

FDA-approved product (cream, topical), marketed as Fluor-Op, Fluorometholone, Fml and 2 more.

Registered studies
37
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fluorometholone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Eye inflammation
  • Hemorrhoid
  • Inflammation

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne; Corticosteroids, plain
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

37registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluorometholone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluorometholone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fluorometholone Study

    NCT07308938 · start 2026-10-31

    Registered record
    Registry ID
    NCT07308938
    Conditions
    Keratitis Bacterial; Corneal Ulcer (Diagnosis)
    Interventions
    Adjunctive Topical Fluorometholone (FML) 0.1%; Standard Topical Antibiotic Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-31
    Completion
    2030-12-31
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratitis Bacterial; Corneal Ulcer (Diagnosis)
    InterventionAdjunctive Topical Fluorometholone (FML) 0.1%; Standard Topical Antibiotic Therapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • Innovative Tube Trabeculectomy for Advanced and Refractory Glaucoma: A Randomized Controlled Trial

    NCT07755761 · start 2026-08-01

    Registered record
    Registry ID
    NCT07755761
    Conditions
    Glaucoma; Trabeculectomy; Innovative Procedures
    Interventions
    Innovative Tube Trabeculectomy; Conventional Trabeculectomy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-08-01
    Completion
    2028-08-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Trabeculectomy; Innovative Procedures
    InterventionInnovative Tube Trabeculectomy; Conventional Trabeculectomy
    PhaseNot applicable
    Registry statusRecruiting

  • Vevye + Flarex Combination Therapy for Dry Eye

    NCT07553455 · start 2026-04-03

    Registered record
    Registry ID
    NCT07553455
    Conditions
    Dry Eye
    Interventions
    Vevye(Cyclosporine 0.1% Ophthalmic Solution); Flarex
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Enrolling by invitation
    Start
    2026-04-03
    Completion
    2026-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionVevye(Cyclosporine 0.1% Ophthalmic Solution); Flarex
    PhasePhase 4
    Registry statusEnrolling by invitation

  • Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT

    NCT06498440 · start 2024-09-01

    Registered record
    Registry ID
    NCT06498440
    Conditions
    Open Angle Glaucoma; Ocular Hypertension; Postoperative Inflammation
    Interventions
    Ketorolac 0.5% Eye Drops; Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-09-01
    Completion
    2025-07-01
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension; Postoperative Inflammation
    InterventionKetorolac 0.5% Eye Drops; Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops
    PhasePhase 4
    Registry statusUnknown

  • The OPTIMISE Study

    NCT05716945 · start 2024-07-29

    Registered record
    Registry ID
    NCT05716945
    Conditions
    Pseudophakic Bullous Keratopathy; Fuchs' Endothelial Dystrophy; Intraocular Pressure
    Interventions
    Fluorometholone 0.1% Oph Susp; Dexamethasone 0.1% ophthalmic suspension; Stop steroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-07-29
    Completion
    2029-03
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudophakic Bullous Keratopathy; Fuchs' Endothelial Dystrophy; Intraocular Pressure
    InterventionFluorometholone 0.1% Oph Susp; Dexamethasone 0.1% ophthalmic suspension; Stop steroids
    PhasePhase 4
    Registry statusRecruiting

  • Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis

    NCT06209879 · start 2024-02-05

    Registered record
    Registry ID
    NCT06209879
    Conditions
    Dry Eye Syndromes
    Interventions
    SYSTANE™ Hydration Lubricant Eye Drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-02-05
    Completion
    2024-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndromes
    InterventionSYSTANE™ Hydration Lubricant Eye Drops
    PhasePhase 4
    Registry statusUnknown

  • Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK

    NCT05587231 · start 2022-10

    Registered record
    Registry ID
    NCT05587231
    Conditions
    Steroid Ophthalmic Insert
    Interventions
    Dextenza 0.4Mg Ophthalmic Insert; Topical Fluorometholone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-10
    Completion
    2024-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSteroid Ophthalmic Insert
    InterventionDextenza 0.4Mg Ophthalmic Insert; Topical Fluorometholone
    PhasePhase 4
    Registry statusUnknown

  • Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease

    NCT06876116 · start 2022-09-01

    Registered record
    Registry ID
    NCT06876116
    Conditions
    Dry Eye Disease (DED)
    Interventions
    Fluorometholone 0.1% ophthalmic solution; Cyclosporine 0.05% eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-09-01
    Completion
    2024-05-24
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease (DED)
    InterventionFluorometholone 0.1% ophthalmic solution; Cyclosporine 0.05% eye drops
    PhasePhase 4
    Registry statusCompleted

  • Topical Insulin Versus Autologous Serum After Corneal Surgeries

    NCT05331859 · start 2022-05

    Registered record
    Registry ID
    NCT05331859
    Conditions
    Corneal Epithelial Wound
    Interventions
    Insulin; autologous serum (AS); conventional
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-05
    Completion
    2022-09
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Epithelial Wound
    InterventionInsulin; autologous serum (AS); conventional
    PhasePhase 1
    Registry statusUnknown

  • Effect of Various Treatment Modalities on Dendritic Vial Ulcer

    NCT05313828 · start 2022-03-18

    Registered record
    Registry ID
    NCT05313828
    Conditions
    Corneal Ulcer
    Interventions
    Acyclovir; Tobramycin; Fluorometholone; Sodium Hyaluronate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-03-18
    Completion
    2022-07-20
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcer
    InterventionAcyclovir; Tobramycin; Fluorometholone; Sodium Hyaluronate
    PhaseNot recorded
    Registry statusUnknown

  • Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye

    NCT05131152 · start 2021-12-01

    Registered record
    Registry ID
    NCT05131152
    Conditions
    Dry Eye
    Interventions
    Cyclosporine; oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2024-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionCyclosporine; oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
    PhaseNot applicable
    Registry statusUnknown

  • FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial

    NCT04149210 · start 2021-08-19

    Registered record
    Registry ID
    NCT04149210
    Conditions
    Trachomatous Trichiasis (TT); Eye Diseases; Eyelid Diseases; Trachomatous; Trichiasis
    Interventions
    Fluorometholone 0.1% Oph Susp; Artificial Tears
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-08-19
    Completion
    2024-11-30
    Enrolment
    2,410

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrachomatous Trichiasis (TT); Eye Diseases; Eyelid Diseases; Trachomatous +1 more
    InterventionFluorometholone 0.1% Oph Susp; Artificial Tears
    PhasePhase 3
    Registry statusCompleted

  • The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization

    NCT05011916 · start 2021-08-10

    Registered record
    Registry ID
    NCT05011916
    Conditions
    Corneal Neovascularization
    Interventions
    KDR2-2 suspension eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2021-08-10
    Completion
    2022-08-09
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Neovascularization
    InterventionKDR2-2 suspension eye drops
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Tolerability Comparison of Flarex to Lotemax SM

    NCT07588074 · start 2021-05-01

    Registered record
    Registry ID
    NCT07588074
    Conditions
    Ocular Inflammation; Keratoconjunctivitis; Dry Eye Disease (DED); Post-operative Complications; Kerato Conjunctivitis Sicca; Dry Eye Syndromes; Postoperative Complications
    Interventions
    Fluorometholone Acetate Ophthalmic Suspension 0.1%; Loteprednol Etabonate Ophthalmic Gel 0.38%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-05-01
    Completion
    2021-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Inflammation; Keratoconjunctivitis; Dry Eye Disease (DED); Post-operative Complications +3 more
    InterventionFluorometholone Acetate Ophthalmic Suspension 0.1%; Loteprednol Etabonate Ophthalmic Gel 0.38%
    PhasePhase 4
    Registry statusCompleted

  • Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients

    NCT05771194 · start 2021-02-01

    Registered record
    Registry ID
    NCT05771194
    Conditions
    Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid
    Interventions
    Routine preoperative and postoperative anti-infection therapy; artificial tear therapy; Cleaning, hot compresses and massage of the meibomian gland
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-02-01
    Completion
    2022-07-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid
    InterventionRoutine preoperative and postoperative anti-infection therapy; artificial tear therapy; Cleaning, hot compresses and massage of the meibomian gland
    PhasePhase 4
    Registry statusCompleted